About us

Located in Delaware,USA, EliveBio Inc. was founded by a team of successful entrepreneurs with decades of experience in synthetic biology and bio-pharmaceuticals. Medicine has evolved over the last few decades from considering all microorganisms to be potential health threats, to identifying their role in maintaining physiologic functions of the human host.
Using our revolutionary synthetic biology platform, a “safe” bacteria can be programmed to enter a target organ, “sense” the disease status, produce a therapeutic drug molecule, and self-destruct upon completion. This in situ drug production greatly reduces the off-target effects, and has a wide range of applications that can be utilized to help improve the patient’s quality of life.

Current Projects

Live Anticancer Therapy

Advancements in cancer treatment, including targeted therapy and immunotherapy, offer hope for curing various cancer types. However, challenges persist, such as toxicity to normal tissues, deep tumor treatment difficulties, and drug resistance. Live tumor-targeting bacteria, engineered for controlled drug delivery, provide a promising solution. These bacteria can be used alone or in combination with other therapies to improve clinical outcomes, specifically targeting respiratory tract cancers.